<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432389</url>
  </required_header>
  <id_info>
    <org_study_id>000013/BT</org_study_id>
    <nct_id>NCT04432389</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture</brief_title>
  <acronym>ALLOB-TF2</acronym>
  <official_title>Phase IIb, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bone Therapeutics S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bone Therapeutics S.A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the majority of tibial fractures heal normally, some fractures may not heal within&#xD;
      the usual time frame and is known as delayed bone healing within 4 to 6 months and absence of&#xD;
      bone healing within 9 to 12 months in the most severe case of. Several factors can increase&#xD;
      the risks of delayed healing complications like, for example, smoking, violent shocks (for&#xD;
      example, due to a road accident) or even the type of fracture (an open fracture). The&#xD;
      location of the fracture is also an important factor: among the bones of the arms and legs,&#xD;
      the tibia is known for being the most at risk for complications. At tibial fracture with&#xD;
      several risk factors could lead to delayed complications and interfere with patient daily&#xD;
      life and reduce the quality of life.&#xD;
&#xD;
      The study drug, ALLOB®, is constituted of bone cells produced from the bone marrow of healthy&#xD;
      adult donors. Preclinical studies have shown that ALLOB® cells are capable of forming bone&#xD;
      and repairing fractures. When directly injected into a fracture, ALLOB® should therefore&#xD;
      promote the healing of the fracture by re-establishing a healthy environment and stimulating&#xD;
      bone production. To date, there is no treatment for fractures considered at risk of delayed&#xD;
      complications. The current practice on diagnosis of complications is to wait at least 6-12&#xD;
      months before considering alternative interventions to promote fracture healing. The&#xD;
      injection of ALLOB® quickly after the fracture should stimulate bone healing, reduce healing&#xD;
      time, reduce complications, and improve the quality of life for the patient. ALLOB® has&#xD;
      already shown preliminary evidence of effectiveness in the treatment of delayed bone healing&#xD;
      fractures (ALLOB-DU1 clinical trial), including tibial fractures (8 patients). With this&#xD;
      study, the Sponsor will evaluate whether ALLOB® promotes the healing of tibial fractures&#xD;
      compared with placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of subjects with a radiological success at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>A radiological success is defined as a subject with a Radiological Union Score for Tibia (RUST) above the threshold value predictive of a normal bone healing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with radiological success at Week 16, Week 20 and Month 6</measure>
    <time_frame>16 weeks - 20 weeks - 6 months</time_frame>
    <description>A radiological success is defined as a subject with a Radiological Union Score for Tibia (RUST) above the threshold value predictive of a normal bone healing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Radiographic Union Score for Tibia (RUST) at Week 12, Week 16, Week 20 and Month 6 compared to baseline visit</measure>
    <time_frame>weeks 12 - 16 - 20 - 6 months</time_frame>
    <description>Radiological fracture healing is defined by a radiological fracture union evaluated and adjudicated by Independent Radiologists.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Tibial Fracture</condition>
  <arm_group>
    <arm_group_label>ALLOB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of ALLOB at fracture site (4 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single injection of Placebo at fracture site (4 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLOB</intervention_name>
    <description>After thawing, ALLOB® is a ready-to-use product for local administration at fracture site.</description>
    <arm_group_label>ALLOB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo injected is a saline solution injectable grade (4 mL of 0.9% NaCl) filled in single-dose vial</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women at least 18 years of age&#xD;
&#xD;
          2. Subject diagnosed with a fresh proximal, midshaft or distal tibial fracture with&#xD;
             definitive reduction performed with nail(s) and wound closure within 1 week of&#xD;
             fracture occurrence&#xD;
&#xD;
          3. Mechanism of injury at risk of DU/NU: fracture occurring because of a high energy&#xD;
             impact&#xD;
&#xD;
          4. At increased risk of DU/NU defined by:&#xD;
&#xD;
               -  Severe open fracture (Gustilo-Anderson grade IIIa and IIIb) OR&#xD;
&#xD;
               -  Open (Gustilo-Anderson grade I-II) or closed (Tscherne grade II-III) fracture&#xD;
                  with at least one additional risk factor among smoking , comminuted fracture or&#xD;
                  cortical continuity (0-50%)&#xD;
&#xD;
          5. Ability to obtain a written, dated, and signed informed consent prior to any study&#xD;
             related procedures and ability to understand and comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Definitive reduction at the fracture site under investigation performed with plate,&#xD;
             screw or external fixator&#xD;
&#xD;
          2. Subjects who did not receive a standard antibiotic prophylaxis before definitive&#xD;
             reduction at the fracture site under investigation&#xD;
&#xD;
          3. Intra-articular tibial pilon and/or plateau fracture at the site under investigation&#xD;
&#xD;
          4. Known osteomyelitis at the fracture site under investigation&#xD;
&#xD;
          5. Bone defect post-definitive reduction greater than 1cm at least on 2 cortices at the&#xD;
             fracture site under investigation&#xD;
&#xD;
          6. Fracture requiring vascular surgery at the site under investigation&#xD;
&#xD;
          7. Pathological fractures as judged by the Investigator, such as tumor or metabolic bone&#xD;
             disease&#xD;
&#xD;
          8. Bifocal or multifocal fracture at the site under investigation&#xD;
&#xD;
          9. Presence of fever (defined as body temperature ≥ 38°C) or other signs/symptoms&#xD;
             suggestive of active infection before randomization&#xD;
&#xD;
         10. Severe brain trauma with a Glasgow Coma Scale (GCS) [3 - 8] or severe spinal cord&#xD;
             injury with impossibility of weight-bearing&#xD;
&#xD;
         11. Current or history (within 5 years) of any neoplasia (except for basal cell carcinoma&#xD;
             of the skin and for carcinoma in situ of the cervix that has been treated with no&#xD;
             evidence of recurrence)&#xD;
&#xD;
         12. Known metabolic diseases potentially interfering with bone healing as judged by the&#xD;
             Investigator, such as thyroid dysfunction, Paget disease or severe osteoporosis&#xD;
&#xD;
         13. Planned or history of solid organ transplantation or bone marrow transplantation&#xD;
&#xD;
         14. Known disease, including genetic disease, that may possibly need solid organ&#xD;
             transplantation&#xD;
&#xD;
         15. Subject with renal impairment requiring dialysis or with clinically significant renal&#xD;
             impairment defined as serum creatinine &gt;2.0 x ULN&#xD;
&#xD;
         16. Clinically significant hepatic function impairment defined as ALT/AST levels &gt; 3x ULN&#xD;
             or total bilirubin levels &gt; 2 x ULN&#xD;
&#xD;
         17. Known hematologic disease as evidenced by hematocrit &lt; 25%, white blood cell &lt;&#xD;
             2,500/ul or platelet values &lt; 100,000/ul without another explanation&#xD;
&#xD;
         18. Subject with an history of long standing poorly controlled chronic hypertension or&#xD;
             diabetes that could put him at risk of needing a kidney transplant later on according&#xD;
             to the Investigator&#xD;
&#xD;
         19. History of hypersensitivity to human biological material including blood and blood&#xD;
             derived products&#xD;
&#xD;
         20. Known allergy to DMSO, dextran, gentamicin and any other aminoglycosides&#xD;
&#xD;
         21. Participation in another interventional clinical study within 3 months prior to&#xD;
             screening&#xD;
&#xD;
         22. Any chronic intake of medication within one month that might affect bone metabolism or&#xD;
             the quality of bone formation such as but not limited to bisphosphonates,&#xD;
             teriparatide, systemic steroids, anticoagulant therapies, methotrexate and other&#xD;
             immunosuppressant drugs or related immunotherapy&#xD;
&#xD;
         23. Previous (within 10 years) treatment with bisphosphonates&#xD;
&#xD;
         24. Current treatment with bone morphogenic protein or any other osteo-biologic&#xD;
             intervention at the site of the tibial fracture&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Godeaux, MD</last_name>
    <phone>+32 (0)71 121000</phone>
    <email>clinicaltrials@bonetherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tf2-Be-05</name>
      <address>
        <city>Anderlecht</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Be-03</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Be-04</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Be-01</name>
      <address>
        <city>Lodelinsart</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Cz-05</name>
      <address>
        <city>Jindřichův Hradec</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Cz-03</name>
      <address>
        <city>Kladno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Cz-04</name>
      <address>
        <city>Nový Jičín</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Cz-02</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Cz-06</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Cz-01</name>
      <address>
        <city>České Budějovice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Fr-06</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>study coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Fr-04</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Fr-01</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Fr-02</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Fr-06</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-de-04</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-de-06</name>
      <address>
        <city>Luebeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-de-02</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-de-01</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Hu-01</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Hu-06</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Hu-05</name>
      <address>
        <city>Kaposvár</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Hu-02</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Hu-04</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Hu-03</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Pl-12</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Pl-08</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Pl-01</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ft2-Pl-07</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Pl-06</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Pl-02</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Es-09</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Es-08</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Es-02</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tf2-Es-03</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Es-07</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Es-06</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Es-05</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tf2-Es-01</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

